Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669600 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
A Phase 2 study, sponsored by Bioverativ, a Sanofi company.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04669600 is a Phase 2 study that has completed, run by Bioverativ, a Sanofi company. The registered enrollment target is 12 participants.
The verdict
NCT04669600, a Phase 2 study, has completed, sponsored by Bioverativ, a Sanofi company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Primary Objective: \- To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP) Secondary Objectives: * To assess the safety and tolerability of BIVV020 * To assess the pharmacokinetics of BIVV020 * To assess the response rate of treatment with BIVV020 * To assess the time to response * To assess the effect of treatment with BIVV020 on the requirement for rescue ITP therapy * To assess the immunogenicity of BIVV020
Interventions
- DRUG SAR445088 (BIVV020)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2023-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04669600
The ClinicalTrials.gov registry entry for NCT04669600 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bioverativ, a Sanofi company, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAR445088 (BIVV020) is the first listed.
NCT04669600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04669600 about?
NCT04669600 is a clinical study titled "A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)". Primary Objective: \- To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP) Secondary Objectives: * To assess the safety and tolerability of BIVV020 * To assess the pharmacokinetics of BIVV020 * To assess the...
What is the current status of trial NCT04669600?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-02-04. Estimated completion is 2023-02-07.
What interventions are being tested in trial NCT04669600?
The interventions under investigation include: SAR445088 (BIVV020) (DRUG).
Who is sponsoring clinical trial NCT04669600?
This trial is sponsored by Bioverativ, a Sanofi company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.